Trial Search Results

Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. rTMS may be a promising treatment option for SUD. In this study, we will demonstrate the feasibility of applying rTMS to Veterans with SUD, examine the efficacy of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

VA Office of Research and Development

Collaborator: Stanford University

Stanford Investigator(s):

Intervention(s):

  • Device: Repetitive transcranial magnetic stimulation (rTMS)

Phase:

N/A

Eligibility


Inclusion Criteria:

   - SCID confirmed diagnosis of SUD, severe

   - Last use of stimulants >1 and <6 weeks

   - Stable medication regimen (no change in dose or agents between 2 weeks prior to the
   start of and throughout the treatment phase of the study)

   - Stable social environment and housing to enable regular attendance at clinic visits.

   - Ability to undergo cognitive testing, fMRI scans, and rTMS (no contraindications)

   - IQ > 80

   - Stable medical health

   - Veteran at Palo Alto VA's Addiction Treatment Services

Exclusion Criteria:

   - Pregnant or lactating female

   - History of prior adverse reaction to TMS

   - On medications thought to significantly lower seizure threshold, e.g.:

      - clozapine

      - chlorpromazine

      - clomipramine

      - bupropion > 400 mg/day

   - Use of direct dopaminergic antagonists or agonists

   - History of seizures or conditions known to substantially increase risk for seizures

   - Implants or medical devices incompatible with TMS

   - Acute or unstable chronic medical illness that would affect participation or
   compliance with study procedures, e.g. unstable angina

   - Unstable psychiatric symptoms that precludes consistent participation in the study,
   e.g.:

      - active current suicidal intent or plan

      - severe psychosis

   - Inability to undergo fMRI scan, e.g. claustrophobia, presence of ferromagnetic objects
   in subject's body

   - Other substance use disorder not in sustained remission

   - Chronic or recurring Axis I psychiatric condition preceding SUD other than PTSD

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jong H Yoon, MD
650-493-5000
Not Recruiting